Page last updated: 2024-11-12
melflufen
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
melflufen: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9935639 |
| CHEMBL ID | 4303060 |
| SCHEMBL ID | 18239898 |
| MeSH ID | M0589708 |
Synonyms (37)
| Synonym |
|---|
| f70c5k4786 , |
| MFF , |
| melphalan flufenamide |
| j 1 |
| melphalan flufenamide [usan:inn] |
| prodrug j 1 |
| j-1 |
| 380449-51-4 |
| unii-f70c5k4786 |
| ethyl (2s)-2-((2s)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanamido)-3-(4-fluorophenyl)propanoate |
| prodrug j-1 |
| j-1 (prodrug) |
| who 9493 |
| l-phenylalanine, 4-(bis(2-chloroethyl)amino)-l-phenylalanyl-4-fluoro-, ethyl ester |
| melflufen |
| j 1 (prodrug) |
| prodrug j1 |
| j1 |
| melphalan flufenamide [usan] |
| melphalan flufenamide [who-dd] |
| melphalan flufenamide [inn] |
| j1 (prodrug) |
| SCHEMBL18239898 |
| DTXSID40191461 |
| melphalan flufenamide (usan/inn) |
| D11865 |
| HY-105019 |
| CS-0024709 |
| ethyl (s)-2-((s)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanamido)-3-(4-fluorophenyl)propanoate |
| 380449-51-4 (free base) |
| Q27277739 |
| CHEMBL4303060 |
| pepaxti |
| ethyl (2s)-2-[[(2s)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate |
| gtpl11605 |
| GLXC-25713 |
| AKOS040752993 |
Research Excerpts
Overview
Melflufen is a novel anticancer peptide-drug conjugate compound for patients with relapsed refractory multiple myeloma. Melflufen rapidly delivers a cytotoxic payload into tumor cells.
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1916663 | Potency index, ratio of Melphalan IC50 to test compound IC50 for cytotoxicity against patient-derived human lymphoma cells assessed as cell growth inhibition incubated for 72 hrs by FMCA assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Melphalan: Recent insights on synthetic, analytical and medicinal aspects. |
| AID1916662 | Cytotoxicity against patient-derived human lymphoma cells assessed as cell growth inhibition incubated for 72 hrs by FMCA assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Melphalan: Recent insights on synthetic, analytical and medicinal aspects. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (31)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (25.81) | 24.3611 |
| 2020's | 23 (74.19) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 42.73
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (42.73) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (19.35%) | 5.53% |
| Reviews | 7 (22.58%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (58.06%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||